文献速递细菌感染、耐药与抗菌药物医院感染防控

停止选择性报告阿莫西林-克拉维酸与处方及艰难梭菌感染的关联:加拿大安大略省2017-2024年生态学研究

Cessation of amoxicillin-clavulanate selective reporting and association with antibiotic prescribing and Clostridioides difficile infection in Ontario, Canada, 2017-2024: an ecological study.
PubMed 文献 · Clin Microbiol Infect · 2026-04-20

该生态学研究分析安大略省2017年1月至2024年6月月度数据,发现对阿莫西林敏感尿分离株报告阿莫西林-克拉维酸药敏的比例从4.1%升至56.7%后,阿莫西林-克拉维酸处方增加(IRR 1.29),社区相关艰难梭菌感染模型估计超额459例。

要点

  • 对阿莫西林敏感菌株报告阿莫西林-克拉维酸药敏与处方增加相关(IRR 1.29)。
  • 该报告变化与模型估计的社区相关艰难梭菌感染超额459例相关。
  • 微生物实验室选择性药敏报告可能影响患者结局。

核心结论

  • 在阿莫西林敏感的尿分离株中报告阿莫西林-克拉维酸药敏与阿莫西林-克拉维酸处方增加及模型估计的社区相关艰难梭菌感染率升高相关。

研究设计与样本

  • 生态学纵向研究,使用2017年1月至2024年6月安大略省居民月度全省汇总数据。
  • 主要暴露为阿莫西林敏感大肠埃希菌和奇异变形杆菌分离株中月度阿莫西林-克拉维酸报告百分比。
  • 采用按年龄和性别分层的负二项回归,并调整呼吸道病毒活动。

主要发现

  • 阿莫西林-克拉维酸处方增加(IRR 1.29;95%CI 1.17-1.43),对照抗生素处方保持稳定(阿莫西林IRR 0.97;95%CI 0.87-1.09)。
  • 与阿莫西林相比,阿莫西林-克拉维酸处方增加36%(IRR 1.36;95%CI 1.23-1.51)。

临床怎么用

  • 临床医生应意识到微生物实验室选择性药敏报告策略可能影响抗菌药物选择及艰难梭菌感染风险。
  • 对阿莫西林敏感尿分离株,应优先考虑窄谱抗生素如阿莫西林,而非阿莫西林-克拉维酸。

局限性

  • 生态学研究设计不能确定个体水平因果关系。
  • 使用月度全省汇总数据,可能存在未测量混杂。
  • 社区相关艰难梭菌感染超额病例为模型估计值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To discourage unnecessary use of amoxicillin-clavulanate (a broader-spectrum antibiotic with high Clostridioides difficile infection risk), selective reporting is used to suppress susceptibility results when the isolate is susceptible to narrower-spectrum antibiotics like amoxicillin. In Ontario, Canada, surveillance data revealed a rapid increase in amoxicillin-clavulanate susceptibility reporting in December 2021, consistent with a cessation of selective reporting in some community laboratories. Our objective was to examine whether increased amoxicillin-clavulanate susceptibility reporting among amoxicillin-susceptible urinary isolates was associated with increased prescribing of amoxicillin-clavulanate and community-associated C. difficile infection (CA-CDI) at a population level. METHODS: We conducted an ecological longitudinal study of Ontario residents from January 2017 to June 2024, using monthly province-wide aggregated data. The primary exposure was monthly percentage of amoxicillin-clavulanate reporting among amoxicillin-susceptible Escherichia coli and Proteus mirabilis isolates. Outcomes included monthly amoxicillin-clavulanate prescribing rates and CA-CDI incidence, while prescribing of amoxicillin, nitrofurantoin, trimethoprim-sulfamethoxazole, ciprofloxacin, and first-generation cephalosporins served as comparators. Analyses used negative binomial regression stratified by age and sex, adjusted for respiratory virus activity. RESULTS: Following an increase in amoxicillin-clavulanate susceptibility reporting from 4.1% (January 2017 to November 2021) to 56.7% (December 2021 to June 2024) among amoxicillin-susceptible isolates, amoxicillin-clavulanate prescribing increased (incidence rate ratio [IRR], 1.29; 95% CI, 1.17-1.43), while comparator antibiotic prescribing remained stable (amoxicillin: IRR, 0.97; 95% CI, 0.87-1.09). Compared with amoxicillin, amoxicillin-clavulanate prescribing increased by 36% (IRR, 1.36; 95% CI, 1.23-1.51). The change in reporting was associated with 459 (95% CI, 336-585) modelled excess cases of CA-CDI from December 2021 to June 2024, compared with the projected CA-CDI incidence if there had been no change in amoxicillin-clavulanate reporting. CONCLUSIONS: Our study suggests that reporting amoxicillin-clavulanate susceptibility among amoxicillin-susceptible urinary isolates is associated with increased amoxicillin-clavulanate prescribing and higher CA-CDI rates based on model-derived estimates, highlighting the impact of selective antibiotic susceptibility reporting by microbiology laboratories on patient outcomes.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Wong MK, Daneman N, Langford BJ, et al. Cessation of amoxicillin-clavulanate selective reporting and association with antibiotic prescribing and Clostridioides difficile infection in Ontario, Canada, 2017-2024: an ecological study. Clin Microbiol Infect. 2026. PMID: 42019678. doi:10.1016/j.cmi.2026.04.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。